National Institute on Alcohol Abuse and Alcoholism; Amended Notice of Meeting

---
identifier: "/us/fr/2024-04115"
source: "fr"
legal_status: "authoritative_unofficial"
title: "National Institute on Alcohol Abuse and Alcoholism; Amended Notice of Meeting"
title_number: 0
title_name: "Federal Register"
section_number: "2024-04115"
section_name: "National Institute on Alcohol Abuse and Alcoholism; Amended Notice of Meeting"
positive_law: false
currency: "2024-02-28"
last_updated: "2024-02-28"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2024-04115"
document_type: "notice"
publication_date: "2024-02-28"
agencies:
  - "Health and Human Services Department"
  - "National Institutes of Health"
fr_citation: "89 FR 14671"
fr_volume: 89
---


#  National Institute on Alcohol Abuse and Alcoholism; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel, PAR-22-102 and PAR-22-103: Investigational New Drug (IND)—enabling and Early-Stage Development of Medications to Treat Alcohol Use Disorder and Alcohol-Associated Organ Damage March 21, 2024, 01:00 p.m. to March 21, 2024, 04:00 p.m., National Institute of Health, National Institute on Alcohol Abuse and Alcoholism, 6700B Rockledge Drive, Bethesda, MD 20892 which was published in the *Federal Register* on February 01, 2024, FR Doc 2024-01998, 89 FR 6530.

This notice is being amended to change the Meeting Format from a Regular Meeting to a Virtual Meeting. The meeting is closed to the public.

Dated: February 21, 2024.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.